CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE [Accessibility Statement] Skip NavigationNASHVILLE, Tenn., Feb. 24, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its 2025 financial results and provide a company update after the market closes on Tuesday, March 3, 2026.A conference call will be held on March 3 at 4:30 p.m. Eastern Time to discuss the results and update.The link ...

Company Overview - Cumberland Pharmaceuticals is a specialty pharmaceutical company with a portfolio of FDA-approved branded products [6] - The company has three national sales divisions and several catalysts for new growth opportunities [6] - Cumberland has a proven record of successful product development and product acquisition [6] Product Portfolio - Acetadote is an IV treatment for acetaminophen overdose, developed and registered by Cumberland [11] - Caldolor is an injectable delivery of ibuprofen with antipyretic, analgesic & anti-inflammatory properties, approved for use in adults, children and newborns [15] - Kristalose is a unique crystalline formulation of lactulose, a prescription strength laxative [20] - Vibativ is an IV antibiotic that treats life-threatening infections resulting from gram-positive bacteria [24] - Sancuso is an FDA-approved transdermal system for chemotherapy-induced nausea and vomiting [29] - Ifetroban is Cumberland's first new chemical entity, a potent, selective antagonist of thromboxane receptor [30] Financial Performance (2024) - Net revenues were $37.9 million [51] - Gross profit was $31.3 million [51] - Adjusted earnings were $(1.0) million [51] - Cash and securities totaled $18.0 million as of December 31, 2024 [52] - The company has tax carryforward credits of $53 million available [52]